News

The trial compared experimental drug alemtuzumab with approved multiple sclerosis (MS) drug Rebif which showed 55% reduction in relapse rate in 2 annual cycles of alemtuzumab treatment as

Dermik’s product portfolio consists therapeutic and aesthetic dermatology brands like: BenzaClin for the treatment of acne, Carac for the treatment of keratoses and Sculptra, a facial injectable for

Rigosertib is a patent protected multi-kinase inhibitor of critical pathways important in the growth and proliferation of cancer cells. As per the terms of the agreement, SymBio will

Under the agreement, the researchers of ETH Zurich’s Institute of Molecular Systems Biology will use IBM’s SmartCloud Enterprise and data management solutions of CloudBroker for identifying around 250

After the transaction, Global Pharm obtained the new business license for Bozhou Xinghe, with registered capital of $3.1m. Under the terms of this acquisition, Global Pharm will pay

The products are based on the hormones ethinylestradiol (estrogen) and drospirenone. The EPO’s decision was backed by an appeal from Hexal (Sandoz) which was filed in 2006 against

The double-blind, randomized and placebo-controlled trial will recruit around 48 healthy subjects and 20 HCV genotype 1 treatment naive patients in the US. Achillion president and CEO Michael

China-based Chongqing Lummy is engaged in research, development, manufacture and sale of anti-infective, oncology and nutritional parenteral products. With this agreement, Sagent intends to strengthen its presence in

The expansion helps CIS display platform for the discovery of biological therapeutics, diagnostics and reagents using Tecan liquid handling robots and screening equipment. The development further brings additional